Harvard Bioscience (HBIO) Scheduled to Post Quarterly Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) will be announcing its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $28.15 million for the quarter, compared to analysts’ expectations of $27.80 million. Harvard Bioscience had a positive return on equity of 2.75% and a negative net margin of 3.04%.

Harvard Bioscience Stock Up 0.3 %

Harvard Bioscience stock traded up $0.01 during mid-day trading on Tuesday, reaching $3.72. 126,720 shares of the company were exchanged, compared to its average volume of 86,727. The business has a fifty day moving average of $4.21 and a 200 day moving average of $4.47. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.92 and a current ratio of 1.85. The firm has a market cap of $161.45 million, a P/E ratio of -46.37 and a beta of 1.42. Harvard Bioscience has a 12-month low of $3.44 and a 12-month high of $6.29.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.